Context: Deletions on chromosomes 1p and 19q have been shown to correlate with prognosis and chemosensitivity in anaplastic oligodendrogliomas. In glioblastoma multiforme (GBM), the impact on prognosis of these alterations in GBM is unclear.
T he rapidly expanding field of molecular genetics has identified many genetic alterations in gliomas. With few exceptions, correlations of these alterations with treatment response and outcome, is poor. Of notable exception are deletions on chromosomes 1p and 19q, which are found in 27% to 85% of oligodendrogliomas. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] In anaplastic oligodendrogliomas (AOs), 1p deletions strongly correlate with chemoresponsiveness to procarbazine, lomustine, vincristine and temozolomide chemotherapeutic regimens, approaching 100% in some studies versus 25% in intact tumors. 5, 7, 8 Deletions of 19q are also correlated with chemoresponsiveness in AOs. 5, 7, 8 In addition, prolonged progression free survival is correlated with 1p and 19q deletions in AOs, independent of chemotherapy. 2, 5, [7] [8] [9] [10] Due to the clinical utility of detecting 1p and 19q chromosomal deletions in AOs, there is an interest in determining whether a subset of glioblastoma multiforme (GBM) demonstrate similar genetic alterations, and whether such alterations afford the same treatment response and prognostic implications. Currently, the usefulness of this information is unclear in GBM. 1p and 19q codeletions have been retrospectively observed in a small percentage of GBM. Studies examining impact on prognosis of 1p and 19q deletions in GBMs have yielded conflicting results. [1] [2] [3] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The purpose of this study was to identify patients with a pathologic diagnosis of GBM who had evidence of 1p or 19q deletions by flourescence in situ hybridization (FISH) and correlate these results with clinical findings and length of survival.
METHODS AND MATERIALS
A search of the pathology files from 2001 to 2006 was performed to identify cases of GBM, which were also evaluated for deletions of chromosomes 1p and 19q.
Cases in which the diagnosis was made solely on outside materials and cases in which the diagnosis was in question were excluded from the study. Cases with codeletion of 1p and 19q (N = 9; 6 males and 3 females; mean age 58.4 y) were not included in the data analysis due to the fact that characterization of the chromosomal abnormalities in this group by polymerase chain reaction (PCR) was incomplete N = 3: a 34-year-old male with partial deletions of 1p and 19q, consistent with GBM, was lost to follow-up at 2 months; a 46-year-old female with chromosomal imbalances of both chromosomes 1p and 19q arms, with aneuploid cytogenetics, more consistent with a GBM who survived 42 months; and a 63-year-old male with only 1p PCR loss of heterozygosity (LOH) results of LOH of the entire 1p arm, more consistent with AO who survived 13 months. In the remaining tumors, the possibility that some could be high-grade oligodendrogliomas or highgrade-mixed gliomas has not been fully excluded. Again, due to small size and incomplete characterization of the deletions, no real conclusions can be drawn from this group.
A total of 337 GBMs were evaluated. A control group was then selected at random from the 1p and 19q intact patient population for purposes of comparison.
For 337 tumors, FISH analysis for loss of 1p was performed. Of 337 patients, 271 were evaluated for loss of 19q by FISH. Four-micron-thick sections were cut onto positively charged slides. The unstained slide was deparaffinized in xylene and rehydrated in graded alcohols and distilled water. Cell conditioning was performed in a target retrieval solution (DAKO, Carpinteria, CA) at 901C in a water bath for 40 minutes, followed by cooling at ambient temperature for 20 minutes, then Proteinase K (Roche, Indianapolis, IN) for 6 minutes at 251C. Probes were applied to the appropriate slides (see below), and then the DNA target was denatured at 901C for 6 minutes on a heat block and hybridized at 371C for 16 to 18 hours. The coverslip was removed by washing in 2 Â standard saline citrate (SSC), and excess probe was removed with 0.5 Â SSC stringency washes, followed by graded SSC stringency washes. The digoxigenin-labeled probe was visualized using fluorescein isothiocyanate-antidigoxigenin (Roche). Nucleated cells were identified using 4 0 , 6-diamidino-2-phenylindole counterstain.
From 2001 to early 2004 (156 of 336 tumors), probes specific to chromosome 1p36 and 1q12 were used. The 1q12 probe (spectrum orange-labeled CEP1 probe, Vysis, Downers Grove, IL) was used as a referencecontrol for chromosome 1 and was applied at a dilution of 1:10. A digoxigenin-labeled telomeric probe mapping to chromosome 1p36 (p58 clk-1 DNA probe, Ventana, Tucson, AZ) that identifies the cell division cycle2-like 1 (CDC2L1) gene also was applied as a locus-specific label. Starting early in 2004 (181 of 337 patients), a 1q25 probe (spectrum green-labeled probe, Vysis, Downers Grove, IL) was used as the reference-control signal. Separate slides were made for evaluation of 19q. Probes specific to chromosomes 19p13 and 19q13 were used. The 19p13 probe (spectrum orange-labeled LSI probe, Vysis, Downers Grove, IL) was used as a reference-control label to the short arm of chromosome 19. The 19q13 probe (spectrum green-labeled LSI probe, Vysis, Downers Grove, IL) was used as a locus-specific label of the long arm of chromosome 19 .
The area of interest on each slide after staining was analyzed using an epifluorescent microscope equipped with 6-diamidino-2-phenylindole /fluorescein isothiocyanate/Texas red band-path filters (Axioplan 2, Zeiss, Gottingen, Germany). Forty cells containing a minimum of 2 control signals were counted and a ratio of locusspecific to control signals was determined. A target/control signal ratio of less than or equal to 0.7 was interpreted as representing loss of the target (1p36 or 19q13), that is, allelic loss of 1p or 19q. A signal ratio of greater than or equal to 0.8 was interpreted as representing no evidence of allelic loss, that is, 1p or 19q intact.
A search of the electronic medical record was used to determine sex, age at the time of diagnosis, treatment (including chemotherapy and radiation therapy), and survival. A Cox regression was used to compare survival among those groups with isolated 1p loss, isolated 19q loss, and a control group (age and sex matched) of 1p and 19q intact tumors.
RESULTS
A total of 337 GBMs were evaluated for deletions on chromosomes 1p or 19q. Seventeen tumors (5.1%) were found to have isolated 1p deletions. Eighteen patients (5.3%) had isolated 19q deletions. The 1p and 19q intact control group was made up of 20 patients. There were no obvious morphologic differences between the tumors in each group. Tables 1 and 2 summarize the clinical and tumor characteristics of each group.
Control Group
The 1p and 19q intact patient population was made up of 13 males (65%) and 7 females (35%) and had a mean age of 60 years (range: 40 to 80 y) at the time of initial surgery. Tumor size ranged from 1 to 6.2 cm, with a mean of 4.2 cm. Four tumors (20%) were multicentric/ multifocal at the time of initial surgery. The location of the tumor operated on was as follows: temporal lobe N = 5 (25%), parietal lobe N = 4 (20%), frontal lobe N = 2 (10%), frontal lobe with extension into the corpus callosum N = 2 (10%), frontal-temporal lobes N = 2 (10%), frontal-parietal lobes N = 2 (10%), right temporal-parietal lobes N = 1 (5%), occipital lobe N = 1 (5%), and 1 (5%) multifocal tumor involving the left parietal, right occipital, and left frontal lobes. Of the surgically targeted lesions, 13 tumors were situated on the right side (65%) and 6 (30%) were situated on the left side at the time of initial surgery. A biopsy was initially performed on 4 tumors (20%), with one going on to subtotal resection. Subtotal resections were initially performed on 9 tumors (45%). Seven (35%) tumors underwent gross total resection. Postoperative combined radiotherapy and chemotherapy was used to treat 8 patients (40%) and 2 had radiotherapy alone (10%). The mean survival in this group was 16.4 months (range: 1 to 59 mo). Six patients were alive at last follow-up (30%). Four patients had 1 month of follow-up, and 2 others had 9 and 55 months of follow-up.
1p Deleted Group
The 1p-deleted group was comprised of 9 males (53%) and 8 females (47%). Mean age at initial pathologic diagnosis was 61 years (range: 35 to 84 y).
Tumor size in this group ranged from 1.1 to 7.9 cm in greatest dimension, with a mean of 4.5 cm. Four patients (24%) had multifocal/multicentric disease. Initial surgical locations were as follows: frontal lobe N = 8 (47%), temporal lobe N = 4 (24%), parietal N = 3 (18%), and right temporal and right occipital N = 1 (6%). Nine tumors were situated on the right side (53%), and 6 were located on the left side (35%). One tumor extended into the corpus callosum at the time of initial surgery. One tumor was noted to be bilateral at the time of initial surgery. A biopsy alone was initially performed on 3 tumors (18%). Subtotal resections were performed on 7 (41%) tumors, with one patient requiring a second subsequent subtotal resection. Seven tumors initially underwent gross total resections (41%). Combined postoperative radiotherapy and chemotherapy was administered in 8 of 17 patients (47%), and radiotherapy alone in 3 of 17 (18%). Mean survival for this group was 10.8 months (range: 1 to 50 mo). Five patients (29%) were alive at last follow-up (8, 11, 16, 44 , and 50 mo).
19q Deleted Group
The 19q-deleted group was made up of 7 males (39%) and 11 females (61%). Mean age for this group at the time of initial pathologic diagnosis was 56 years (range: 25 to 76 y). Tumors in this group ranged from 1.5 to 8.1 cm in greatest dimension, with a mean of 4.4 cm. Two patients (11%) had multifocal/multicentric disease at the time of initial surgery. Initial surgical locations were as follows: parietal lobe N = 7 (39%), frontal N = 4 (22%), temporal N = 3 (17%), corpus callosum N = 1 (6%), frontal-parietal lobes N = 1 (6%), parietal-occipital lobes N = 1 (6%), and temporal-occipital lobes N = 1 (6%). Five tumors were situated on the right side (28%) and 12 on the left side (66%). A biopsy was initially performed on 8 patients (44%); 3 of these patients later underwent subtotal resection. Subtotal resection was initially performed on 4 tumors (22%), with 2 going on to gross total resection. A gross total resection was initially performed on 6 tumors (33%), one of which had 2 subsequent biopsies demonstrating GBM and 2 of which had 2 subsequent resections demonstrating GBM. Eight patients (44%) received combined radiation therapy and chemotherapy, and chemotherapy alone was administered in one patient (6%). The mean survival for 19q-deleted tumors was 8.4 months (range: 1 to 17 mo). Three patients (17%) were alive at last follow-up (7, 10, and 10 mo).
Adjusting for sex, age, and chemotherapy, the 19q deleted group had a significantly lower survival (hazard ratio = 2.8, P = 0.025) compared with the 1p deleted and control groups. No survival benefit was seen in the 1p or 19q deleted groups (Fig. 1) .
DISCUSSION
For the last few decades, it has been well recognized that oligodendroglial tumors have a more favorable response to chemotherapy. 5, 8 This was confirmed in multiple large studies. 4, 8 It was subsequently noted that this chemosensitivity correlated with large deletions on chromosomes 1p and 19q. 4, 5, [7] [8] [9] Studies have also noted a treatment-independent positive effect on outcome in 1p and 19q deleted patients. 2,5,7-10 Similar results have been observed in mixed gliomas or oligoastroctyomas. 2, 7, 8, 10 Owing to the well published clinical utility of detecting 1p and 19q chromosomal deletions in oligodendrogliomas, there is an interest in determining whether a subset of GBMs demonstrate similar genetic alterations, and whether such alterations, if present in GBMs, have the same treatment response and prognostic implications. Studies in this area are limited and methods of detection vary between studies. In the current study, the rates of deletion detection by FISH, a widely used clinical methodology, were 5.1% for chromosome 1p deletions and 5.3% for chromosome 19 q deletions. These rates are lower than those reported by others in the literature (10% to 25% for 1p deletions and 6% to 35% for 19q deletions). [1] [2] [3] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The majority of these other studies used other methodologies including comparative genomic hybridization (CGH) or PCR microsatellite LOH to detect deletions. A recently published review of 1p status in 108 adult astrocytic tumors (including 77 GBM) noted partial deletion in 22% of astrocytomas and 34% of glioblastomas using a chromosome 1 tile path array; total 1p deletions, similar to those typically encountered in oligodendrogliomas, were only observed in 2% of tumors. 22 It would seem that a subset of GBM demonstrates partial deletions on chromosomes 1p and 19q but that the deletions are typically smaller than those encountered in oligodendrogliomas and the detection rates are dependent somewhat on the methodologies used. Large deletions involving the whole 1p and 19q arms characterize oligodendrogliomas, whereas small interstitial deletions are more commonly seen in GBM. FISH generally underestimates the incidence of deletions on chromosome 1p and 19q, as it focuses on a single locus for each chromosome. In the case of oligodendrogliomas, these loci examined by FISH are invariably detected, given the loss of most or all of the 1p and 19q arms. Smaller losses on these chromosomes, more commonly encountered in GBM, may occur at other sites along the chromosome. Other methodologies, including PCR or CGH, are more likely to capture these losses. It is the large deletions that have been correlated with chemoresponsiveness and improved prognosis. 5, 10, 12 As our lab routinely uses FISH, probably the most widely used methodology in assessing for glioma deletions, this accounts for our somewhat lower observed incidence of deletions among our GBM population as compared with other studies using PCR or CGH methods.
The reported impact on prognosis in 1p/19q deleted GBM has been mixed in the literature. In 2002, Schmidt and colleagues reported their experience in 97 GBM patients and observed a survival benefit in doubly deleted tumors (22.2 vs. 10.7 mo). 21 Homma and colleagues, 13 in assessing 420 GBM patients, reported a 20.5 month survival in doubly deleted tumors, 13.2-month survival in 1p deleted tumors, and 9.6-month survival in intact patients. Both of these studies used PCR-based methodologies to assess 1p and 19q status. In contrast, both Houillier et al, 14 in studying 220 GBM by PCR, and Shih et al, 16 in evaluating 75 GBM by PCR, reported no survival benefits in the tumors with deletions.
In the current study, 1p and 19q deletions were not found to improve survival of patients with GBM. Treatment varied in our patient population, but combined radiation and chemotherapy was used in a similar proportion among the 3 groups. There is some suggestion that 19q deletions may be deleterious to survival when adjusted for age, sex, and chemotherapy; however, owing to the low number of patients with these deletions, the significance and reproducibility of this is unclear.
Although further study with larger numbers would be useful, data from this study would suggest that there is no added benefit to evaluating 1p and 19q status by FISH in the majority of GBM. Currently, there seems to be a lack of concensus about clinical relevance of the smaller chromosomal deletions on chromosomes 1p and 19q, which are detected in a subset of GBM using other molecular-based methodologies. The presence of large deletions in a tumor diagnosed as GBM may be indicative of oligodendroglial lineage and potential chemoresponsiveness. One strategy would be to use FISH to screen for such double deleted tumors; evidence of deletions by FISH could be followed up by PCR or CGH evaluation to further delineate the extent of the deletions. 
